News | February 09, 2026
Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Company to launch product after the expiry of semaglutide patent in India
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Subscribe To Our Newsletter & Stay Updated
